Caretaker Medical Adds ECG Patch to the Caretaker® Wireless Continuous Blood Pressure & Patient Monitoring Platform

CHARLOTTESVILLE, Va., Feb. 14, 2020 /PRNewswire/ — Caretaker Medical, a leader in clinical-grade wireless patient monitoring and maker of the Caretaker® wearable patient monitor that utilizes a simple Finger Cuff to measure Real-time “Beat by Beat” Continuous Blood Pressure, Respiration Rate, and other hemodynamic parameters, has incorporated VivaLNK’s FDA-Cleared ECG Patch to their wireless patient monitoring platform.

The Caretaker® patient monitor provides clinicians with continuous, uninterrupted Blood Pressure and Vital Signs data across the full continuum of care in a completely wire-free form factor that maximizes patient mobility and provides a comprehensive view of hemodynamic health.  Clinicians can remotely view patient data from virtually anywhere using the Caretaker App, the CaretakerCloud Remote Monitoring Portal, or via data integration with other monitoring platforms.

“Our patented Pulse Decomposition Analysis method of non-invasive hemodynamic measurements like continuous beat-by-beat Blood Pressure provides clinicians with a view of the patient’s mechanical heart function, and VivaLNK’s reusable ECG Patch reveals the status of the patient’s electrical heart function,” said Jeff Pompeo, Caretaker Medical’s President & CEO.  “Combined, the Caretaker monitoring platform now provides a seamless view of both electrical and mechanical heart health, including waveforms, in a completely wire-free, wearable form factor that doesn’t inhibit patient mobility.”

Both the Caretaker wireless monitor and the VivaLNK ECG Patch are FDA-Cleared and CE-Mark certified and available for purchase from Caretaker Medical and its distributors.  For more information please visit www.CaretakerMedical.net

About Caretaker Medical
Caretaker Medical is a wireless medical device firm focused on developing affordable, innovative, patient monitoring solutions that improve outcomes, increase clinician productivity, and maximize patient mobility.  The wearable Caretaker4® monitor enables uninterrupted wire-free and electrode-free vital signs monitoring throughout the full continuum of care, from clinic and hospital, to patient transport, and home monitoring.  Using a low-pressure finger cuff, Caretaker’s patented Pulse Decomposition Analysis technology non-invasively measures continuous Beat-by-Beat Blood Pressure, and Vital Signs for remote display on the Caretaker® App and other Remote Data Displays.

Media Contact: 
Jeff Pompeo
234251@email4pr.com 
Phone:  +1 (434) 978-7000

View original content to download multimedia:http://www.prnewswire.com/news-releases/caretaker-medical-adds-ecg-patch-to-the-caretaker-wireless-continuous-blood-pressure–patient-monitoring-platform-301005027.html

SOURCE Caretaker Medical Corp.

Staff

Recent Posts

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

SINGAPORE, Dec. 7, 2025 /PRNewswire/ -- AI/ML health-tech startup Respiree has received approval from the Health…

31 minutes ago

AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

SINGAPORE, Dec. 7, 2025 /PRNewswire/ -- ChemLex, a next-generation AI-for-science company, today announced the establishment…

31 minutes ago

Is The DEA in Systemic Collapse: Corruption, Constitutional Violations, and a Seven-Year War Against Marijuana Medical Science

The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…

15 hours ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…

15 hours ago

Secura Bio Presents Extended Follow Up Analyses from Phase 2 PRIMO Trial in Patients with Relapsed/Refractory peripheral T-cell lymphoma at the 2025 American Society of Hematology Meeting

Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…

15 hours ago